Literature DB >> 21642535

Homologous recombination research is heating up and ready for therapy.

Simon N Powell1, Lisa A Kachnic.   

Abstract

Mesh:

Substances:

Year:  2011        PMID: 21642535      PMCID: PMC3116400          DOI: 10.1073/pnas.1106456108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  22 in total

1.  Delaying S-phase progression rescues cells from heat-induced S-phase hypertoxicity.

Authors:  R P VanderWaal; C L Griffith; W D Wright; M J Borrelli; J L Roti
Journal:  J Cell Physiol       Date:  2001-05       Impact factor: 6.384

2.  Influence of double-strand-break repair pathways on radiosensitivity throughout the cell cycle in CHO cells.

Authors:  John M Hinz; N Alice Yamada; Edmund P Salazar; Robert S Tebbs; Larry H Thompson
Journal:  DNA Repair (Amst)       Date:  2005-07-12

3.  Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.

Authors:  Bing Xia; Qing Sheng; Koji Nakanishi; Akihiro Ohashi; Jianmin Wu; Nicole Christ; Xinggang Liu; Maria Jasin; Fergus J Couch; David M Livingston
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

4.  DNA double-strand breaks are not sufficient to initiate recruitment of TRF2.

Authors:  Eli S Williams; Jan Stap; Jeroen Essers; Brian Ponnaiya; Martijn S Luijsterburg; Przemek M Krawczyk; Robert L Ullrich; Jacob A Aten; Susan M Bailey
Journal:  Nat Genet       Date:  2007-06       Impact factor: 38.330

5.  Hyperthermic radiosensitization: mode of action and clinical relevance.

Authors:  H H Kampinga; E Dikomey
Journal:  Int J Radiat Biol       Date:  2001-04       Impact factor: 2.694

6.  Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.

Authors:  Przemek M Krawczyk; Berina Eppink; Jeroen Essers; Jan Stap; Hans Rodermond; Hanny Odijk; Alex Zelensky; Chris van Bree; Lukas J Stalpers; Marrije R Buist; Thomas Soullié; Joost Rens; Hence J M Verhagen; Mark J O'Connor; Nicolaas A P Franken; Timo L M Ten Hagen; Roland Kanaar; Jacob A Aten
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

7.  Rad52 inactivation is synthetically lethal with BRCA2 deficiency.

Authors:  Zhihui Feng; Shaun P Scott; Wendy Bussen; Girdhar G Sharma; Gongshe Guo; Tej K Pandita; Simon N Powell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-08       Impact factor: 11.205

8.  Purified human BRCA2 stimulates RAD51-mediated recombination.

Authors:  Ryan B Jensen; Aura Carreira; Stephen C Kowalczykowski
Journal:  Nature       Date:  2010-10-07       Impact factor: 49.962

9.  Model-predictive control of hyperthermia treatments.

Authors:  Dhiraj Arora; Mikhail Skliar; Robert B Roemer
Journal:  IEEE Trans Biomed Eng       Date:  2002-07       Impact factor: 4.538

Review 10.  The DNA damage response: making it safe to play with knives.

Authors:  Alberto Ciccia; Stephen J Elledge
Journal:  Mol Cell       Date:  2010-10-22       Impact factor: 17.970

View more
  2 in total

1.  Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors.

Authors:  Jonathan G Mehtala; Sandra Torregrosa-Allen; Bennett D Elzey; Mansik Jeon; Chulhong Kim; Alexander Wei
Journal:  Nanomedicine (Lond)       Date:  2014-02-05       Impact factor: 5.307

2.  Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.

Authors:  Rolf D Issels; Lars H Lindner; Jaap Verweij; Rüdiger Wessalowski; Peter Reichardt; Peter Wust; Pirus Ghadjar; Peter Hohenberger; Martin Angele; Christoph Salat; Zeljko Vujaskovic; Soeren Daugaard; Olav Mella; Ulrich Mansmann; Hans Roland Dürr; Thomas Knösel; Sultan Abdel-Rahman; Michael Schmidt; Wolfgang Hiddemann; Karl-Walter Jauch; Claus Belka; Alessandro Gronchi
Journal:  JAMA Oncol       Date:  2018-04-01       Impact factor: 31.777

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.